Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 7, 2022 6:30 AM ESTPatient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution
IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa
BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease
New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant (ESCAPE) to be Presented at ASH
Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities
CAMBRIDGE,... More
